{"id":"tebofortan","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Fundació ACE Institut Català de Neurociències Aplicades","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Fundació ACE Institut Català de Neurociències Aplicades","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TEBOFORTAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:52:52.192912+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:52:57.858102+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TEBOFORTAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:52:58.201664+00:00"}},"allNames":["tebofortan"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Tebofortan's exact mechanism of action is currently unknown, and further research is needed to determine its pharmacological properties and potential therapeutic applications."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tebofortan","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tebofortan","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:27:16.469917","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:53:00.377972+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"tebofortan","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05594355","phase":"PHASE4","title":"Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI","status":"UNKNOWN","sponsor":"Fundació ACE Institut Català de Neurociències Aplicades","startDate":"2021-04-16","conditions":["Mild Cognitive Impairment (MCI)"],"enrollment":100,"completionDate":"2023-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Fundació ACE Institut Català de Neurociències Aplicades","relationship":"Original Developer"}],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Fundació ACE Institut Català de Neurociències Aplicades","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"TEBOFORTAN","companyName":"Fundació ACE Institut Català de Neurociències Aplicades","companyId":"fundaci-ace-institut-catal-de-neuroci-ncies-aplicades","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:53:00.377972+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}